Apoteca Selected By The Johns Hopkins Hospital For Robotic Chemotherapy Compounding - Hawaii News Now - KGMB and KHNL

Apoteca Selected By The Johns Hopkins Hospital For Robotic Chemotherapy Compounding

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.


BALTIMORE, June 11, 2014 /PRNewswire/ -- ApotecaUSA and Loccioni AEA today announced that The Johns Hopkins Hospital has selected APOTECAchemo™ to automate the compounding of its hazardous injectable preparations.  Under the agreement, Johns Hopkins will utilize APOTECAchemo™ robotic technology to compound patient-specific hazardous doses principally for patients at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

APOTECAchemo™ will be used to help satisfy institutional standards for patient and staff safety, quality, reliability and cost control.  The two APOTECAchemo™ robots are expected to automate the compounding process for the majority of hazardous doses produced for patients in Johns Hopkins' inpatient and outpatient settings.

The Johns Hopkins Hospital will be joining a prestigious family of organizations, researchers and clinicians striving to improve safety and management of hazardous IV compounding, currently utilizing APOTECAchemo™.

About Apoteca
APOTECAchemo™ is a sterile, robotic chamber for safely and automatically preparing hazardous compounds for individual patients.  APOTECAchemo™ is the cornerstone of a solution of software and automated devices intended to address the complex and varied needs of advanced pharmacy operations.


©2012 PR Newswire. All Rights Reserved.